GlaxoSmithKline: rare disease drug shows positive results

(CercleFinance.com) - GlaxoSmithKline on Wednesday said that its drug Nucala was the first treatment to show a significant reduction in flares for patients with hypereosinophilic syndrome, a rare inflammatory disorder.


A phase 3 study met its primary endpoint, demonstrating a statistically significant result with 50% fewer patients experiencing a worsening of symptoms requiring an escalation in therapy when treated with mepolizumab compared to placebo, the British drugmaker said.

Hypereosinophilic syndrome, which affects approximately 20,000 people globally, is characterised by an overproduction of eosinophils, a type of white blood cell, causing inflammation and organ damage.

Copyright (c) 2019 CercleFinance.com. All rights reserved.